Financial Performance - The group recorded revenue of approximately HKD 1,535,580,000 for the year, an increase from HKD 1,483,892,000 in the previous year, representing a growth of about 3.1%[2] - The group's profit for the year was approximately HKD 49,522,000, down from HKD 75,072,000 in the previous year, indicating a decline of about 34.1%[2] - The company's revenue for the year ended December 31, 2022, was HKD 1,535,580,000, an increase of 3.5% from HKD 1,483,892,000 in 2021[37] - Gross profit decreased to HKD 414,446,000 from HKD 471,261,000, reflecting a decline of 12.1%[37] - The net profit for the year was HKD 49,522,000, down 34.1% from HKD 75,072,000 in the previous year[37] - The company reported a basic and diluted earnings per share of HKD 0.21, compared to HKD 0.29 in 2021, representing a decrease of 27.6%[39] - The total comprehensive income for the year was HKD (66,150,000), compared to HKD 107,391,000 in the previous year, reflecting a significant decline[39] - The company reported a pre-tax profit of HKD 82,503,000 for the year[85] - The company reported a pre-tax profit of HKD 126,508,000 for the year[87] - The group recorded a consolidated profit of approximately HKD 49,522,000 for the year, a decrease from HKD 75,072,000 in the previous year, primarily due to losses from associates and fair value losses on investment properties[198] Assets and Liabilities - As of December 31, 2022, the group's current assets net value was approximately HKD 1,433,526,000, a decrease from HKD 1,955,767,000 in the previous year[8] - The current ratio was reported at 3.90, down from 5.64 in the previous year, while the debt ratio increased to 3.26% from 0.40%[2][8] - As of December 31, 2022, the equity attributable to the owners of the company was approximately HKD 3,491,416,000, down from HKD 3,855,035,000 in the previous year[9] - Total non-current assets increased to HKD 2,821,835 thousand in 2022 from HKD 2,353,118 thousand in 2021, representing a growth of approximately 19.9%[41] - Total liabilities increased to HKD 3,853,590 thousand in 2022 from HKD 4,225,434 thousand in 2021, a decrease of about 8.8%[43] - The company's equity attributable to owners decreased to HKD 3,491,416 thousand in 2022 from HKD 3,855,035 thousand in 2021, reflecting a decline of approximately 9.4%[43] - Cash and cash equivalents, including bank deposits, totaled HKD 1,368,366 thousand in 2022, compared to HKD 1,892,212 thousand in 2021, a decrease of approximately 27.6%[41] - The total non-current assets amounted to HKD 2,718,593,000 in 2022, up from HKD 2,213,109,000 in 2021, reflecting an increase of approximately 22.7%[142] Operational Strategy - TBM plans to expand its business footprint in mainland China by opening more stores in high-traffic and high-consumption areas, aiming to increase market share and revenue[7] - The group is actively seeking potential merger and acquisition opportunities in Hong Kong and mainland China to further scale its operations[7] - The group intends to support the government's primary healthcare blueprint and is exploring collaborations with other major healthcare groups to enhance preventive care services[5] - The company plans to expand its medical services in mainland China, with a focus on enhancing hospital management capabilities[100] Share Repurchase and Dividends - The group has repurchased a total of 725,586,000 shares at a total cost of HKD 313,165,490 during the year[13] - The group plans to pay a final dividend of HKD 0.12 per share for the year ended December 31, 2022, down from HKD 0.15 per share in 2021[156] - The group declared a final dividend of HKD 0.15 per share, totaling approximately HKD 11,289,000 for the year ended December 31, 2022 (2021: zero)[182] Employee and Operational Costs - Employee costs for the year 2022 totaled HKD 718,292,000, an increase from HKD 656,338,000 in 2021, reflecting a rise in overall employee expenses[129] - The total depreciation of property, plant, and equipment amounted to HKD 51,964,000 in 2022, compared to HKD 42,711,000 in 2021, indicating a 21.5% increase[129] - The company's total employee costs in sales amounted to HKD 567,535,000 in 2022, an increase from HKD 527,895,000 in 2021[129] Regulatory and Compliance - The company has complied with the corporate governance code throughout the year[18] - The company is in communication with the Securities and Futures Commission regarding its resumption application, indicating ongoing regulatory engagement[67] - An independent consultant was hired to review the company's internal controls, and a report has been submitted to the company and the Securities and Futures Commission[68] - The company plans to implement all recommendations from the independent consultant's internal control report before the set deadlines[69] - The company has not applied early for new and revised Hong Kong Financial Reporting Standards that will take effect in 2023 and 2024[75] - The company confirmed that there were no significant impacts on its financial performance and disclosures due to the revised Hong Kong Financial Reporting Standards applied during the year[71] Revenue Sources - Revenue from Hong Kong medical services reached HKD 617,116,000 in 2022, up from HKD 470,447,000 in 2021, indicating a growth of about 31.2%[79] - Revenue from mainland China hospital management and medical services was HKD 476,710,000 in 2022, compared to HKD 453,503,000 in 2021, reflecting an increase of approximately 5.1%[79] - Major customer A accounted for 22% of total revenue in 2022, down from 26% in 2021, indicating a diversification in customer base[115] Impairments and Losses - The company recognized a goodwill impairment loss of HKD 487,000 during the year[100] - The group reported a loss of HKD 1,315,000 related to goodwill impairment in 2022, compared to no such loss in 2021[146] - The expected credit loss for the year was HKD 1,177,000, reflecting a cautious approach to credit risk management[100] - The expected credit loss for other receivables was HKD 1,177,000 in 2022, a decrease from HKD 3,528,000 in 2021, indicating improved credit quality[160] Market Conditions - The group experienced a fair value loss on investment properties of approximately HKD 6,893,000, compared to a fair value gain of HKD 47,653,000 in the previous year, largely due to market contraction caused by the COVID-19 pandemic[200] - The group's share of losses from associates amounted to approximately HKD 5,601,000, a significant decline from a profit of HKD 40,484,000 in the previous year, attributed to temporary business closures due to the COVID-19 pandemic[199]
康健国际医疗(03886) - 2022 - 年度业绩